Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 23:12:1613-1622.
doi: 10.2147/JHC.S523261. eCollection 2025.

Natural Bioactive Compounds Targeting the Wnt/β-Catenin Pathway for the Treatment of Hepatocellular Carcinoma

Affiliations
Review

Natural Bioactive Compounds Targeting the Wnt/β-Catenin Pathway for the Treatment of Hepatocellular Carcinoma

Haoyu Tian et al. J Hepatocell Carcinoma. .

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with limited treatment options and poor prognosis. The Wnt/β-catenin signaling pathway is a key regulator of cellular proliferation, differentiation, and stem cell maintenance, and is frequently dysregulated in HCC, contributing to tumor progression, metastasis, and drug resistance. Natural bioactive compounds (NBCs) have emerged as promising treatments due to their multi-targeted mechanisms, low toxicity, and ability to modulate key oncogenic pathways. This review examines the potential of NBCs to target the Wnt/β-catenin pathway in HCC. Compounds such as curcumin, emodin, gallic acid, and ginsenosides exhibit anti-tumor effects by inhibiting β-catenin nuclear translocation, inducing autophagy, suppressing angiogenesis, and modulating the tumor microenvironment. For example, curcumin inhibits HCC cell proliferation and invasion by downregulating lncRNA expression and EMT markers, thereby inactivating the Wnt/β-catenin signaling pathway. Additionally, alkaloids like tetrandrine and toosendanin reduce metastasis through pathway-specific inhibition and epigenetic modulation. These compounds demonstrate potential as standalone therapies, and also in combination with conventional treatments like sorafenib by enhancing the effectiveness and overcoming resistance. However, challenges such as limited bioavailability, stability, and the intricate interplay of the Wnt/β-catenin pathway with other signaling pathways highlights the need for advanced delivery systems and combination strategies. In conclusion, future research should prioritize clinical validation, precision medicine approaches, and exploration of the role of NBCs in cancer stem cell regulation. Collectively, NBCs targeting the Wnt/β-catenin pathway offer a novel, safer, and multi-faceted approach for improving HCC treatment outcomes, paving the way for their integration into standard therapeutic regimens.

Keywords: Wnt/β-catenin signaling; cancer therapeutics; hepatocellular carcinoma; natural bioactive compounds; pathway modulation.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Illustrates the mechanistic roles of all NBCs discussed below in the relevant pathways.

Similar articles

References

    1. Ganesan P, Kulik LM. Hepatocellular carcinoma: new developments. Clin Liver Dis. 2023;27(1):85–102. doi: 10.1016/j.cld.2022.08.004 - DOI - PubMed
    1. Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158(4):410–420. - PubMed
    1. Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3. doi: 10.1038/s41392-021-00762-6 - DOI - PMC - PubMed
    1. Khalaf AM, Fuentes D, Morshid AI, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma. 2018;5:61–73. doi: 10.2147/JHC.S156701 - DOI - PMC - PubMed
    1. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26. doi: 10.1016/j.devcel.2009.06.016 - DOI - PMC - PubMed

LinkOut - more resources